What is the revenue of Recordati?
Recordati S.p.A. generates annual consolidated net revenues exceeding €2.2 billion to over €2.4 billion (translating to multi-billion-euro financial metrics), confirming its prominent standing as an international specialty pharmaceutical group. The enterprise drives robust top-line performance through the research, development, and global commercialization of proprietary pharmaceutical products targeting rare diseases, primary care, and specialized medical treatments.
Related FAQs
The Menarini Group, headquartered in Florence, is recognized as the largest Italian pharmaceutical company and a major global healthcare enterprise.
The global pharmaceutical market features blockbuster medications that generate tens of billions of dollars in annual sales revenue driven by high patient demand and broad therapeutic indications.
Recordati S.p.A. is an international pharmaceutical group headquartered in Milan, Italy, dedicated to the research, development, manufacturing, and commercialization of specialized healthcare products.
Recordati S.p.A.
Recordati S.p.A. is an international pharmaceutical enterprise specializing in rare diseases, specialty primary care medications, and orphan drugs.
Recordati S.p.A. was founded in 1926 by Giovanni Recordati in Correggio, Italy, initially starting as a small pharmaceutical laboratory dedicated to researching and manufacturing medicinal preparations.
Recordati's corporate mission focuses on reducing the severe impact of rare and devastating diseases by discovering, developing, and providing urgently needed specialty medicines in key therapeutic areas.
Recordati S.p.A.
Recordati S.p.A.
Interest rates provided by the Bank of Mauston fluctuate according to specific deposit product tiers, compounding schedules, and prevailing monetary policy adjustments set by central banking authorities.
Recordati Industria Chimica e Farmaceutica S.p.A., an international pharmaceutical group listed on the Borsa Italiana, maintains a market capitalization fluctuating around €10.4 billion to €10.6 billion (equivalent to approximately ₹1.